{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:08:57Z","timestamp":1792426137754,"version":"4.5.0"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"16","funder":[{"DOI":"10.13039\/501100007289","name":"Kangda College of Nanjing Medical University","doi-asserted-by":"publisher","award":["KD2018KYJJZD001"],"award-info":[{"award-number":["KD2018KYJJZD001"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Kangda College of Nanjing Medical University","doi-asserted-by":"publisher","award":["KD2018JYYJYB008"],"award-info":[{"award-number":["KD2018JYYJYB008"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,7,21]]},"abstract":"<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>To explore more active fluoroquinolone anticancer candidates.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Cancer which can affect almost any part of the body, is most striking and deadliest disease.\nIt is estimated that around one in five people globally develop cancer during their lifetime, and approximately\n10% people eventually die from this disease, and 18.1 million new cancer cases with 9.6\nmillion deaths occurred in 2018. The anticancer agents play an intriguingly role in fighting against cancer,\nand above 100 drugs have already been marketed for this purpose. However, the major drawback of\ncurrent accessible anticancer agents is the low specificity which results in many side effects. Moreover,\ncancer cells have already generated resistance to almost all available drugs, creating an urgent need to\nnovel anticancer agents with high specificity and great efficiency especially towards drug-resistant cancers.\nQuinolone and isatin derivatives were reported to possess promising anticancer activity, high specificity,\nand relatively few side effects. Currently, several quinolone and isatin derivatives such as Voreloxin,\nQuarfloxin, AT-3639, Semaxanib, Sunitinib and Nintedanib have already been introduced in\nclinical practice or under evaluations for the treatment of cancer including drug-resistant cancers, revealing\ntheir potential as novel anticancer agents. Hybrid molecules have the potential to increase the specificity,\nimprove the efficiency, and overcome the drug resistance, so hybridization is a promising strategy\nin the drug discovery. Some of the moxifloxacin-isatin hybrids exhibited considerable activity against\nvarious cancer cells even drug-resistant cells, so it is conceivable that hybridization of quinolone and\nisatin moieties may provide novel anticancer candidates. The structure-activity relationships (SARs)\ndemonstrated that the linkers between quinolone and isatin skeletons were critical for the biological activity,\nand 1,2,3-triazole could exert various noncovalent interactions with biological targets, so introduction\nof 1,2,3-triazole as the linker between the two moieties may provide more efficient anticancer\ncandidates.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To explore more active fluoroquinolone anticancer candidates and enrich the structureactivity\nrelationships of fluoroquinolone-isatin hybrids.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> The synthesized moxifloxacin-isatin hybrids 5a-c, 6a-g and 13a-d were assessed for their anticancer\nactivities against liver cancer cells HepG2, breast cancer cells MCF-7, MCF-7\/DOX, prostate\ncancer cells DU-145 and MDR DU-145 by MTT assay. Hybrid 5b was selected for further evaluation of\nits tubulin polymerization inhibitory activity with combretastatin A-4 as comparison.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Most of the synthesized hybrids were active against the tested cancer cell lines, and the most\nactive hybrid 5b (IC50: 31.3-76.8 \u03bcM) was more potent than vorinostat (IC50: 96.7-&gt;100 \u03bcM), demonstrating\nmoxifloxacin-isatin hybrids are potential anticancer candidates.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The mechanism study revealed that inhibition of tubulin polymerization is at least one of\nthe mechanisms of action for this kind of hybrids.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Other:<\/jats:title>\n<jats:p>The structure-activity relationship was summarized for further rational design of more efficient\nanticancer candidates.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200128144825","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T13:34:57Z","timestamp":1580218497000},"page":"1461-1467","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities"],"prefix":"10.2174","volume":"20","author":[{"given":"Mingli","family":"Yang","sequence":"first","affiliation":[{"name":"Kangda College of Nanjing Medical University, Lianyungang 222000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujun","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Ocean University, Lianyungang 222000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-1392","authenticated-orcid":true,"given":"Zhi","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1021\/cr900208x","volume":"109","author":"Shewach D.S.","year":"2009","unstructured":"Shewach D.S.; Kuchta R.D.; Introduction to cancer chemotherapeutics. Chem Rev 2009,109(7),2859-2861","journal-title":"Chem Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1021\/acs.chemrev.7b00258","volume":"117","author":"Fan W.","year":"2017","unstructured":"Fan W.; Yung B.; Huang P.; Chen X.; Nanotechnology for multimodal dynergistic cancer therapy. Chem Rev 2017,117(22),13566-13638","journal-title":"Chem Rev"},{"key":"ref=3","unstructured":"Cancer control: knowledge into action Available from: WHO","journal-title":"Cancer control: knowledge into action Available from:"},{"key":"ref=4","year":"2018","unstructured":"International Agency for Research on Cancer. Latest global cancer data: Cancer burden rises to 181 million new cases and 96 million cancer deaths in 2018 Available from:2018","journal-title":"Latest global cancer data: Cancer burden rises to 181 million new cases and 96 million cancer deaths in 2018"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejmech.2019.01.017","volume":"165","author":"Gao F.","year":"2019","unstructured":"Gao F.; Zhang X.; Wang T.; Xiao J.; Quinolone hybrids and their anti-cancer activities: An overview. Eur J Med Chem 2019,165,59-79","journal-title":"Eur J Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejmech.2019.01.047","volume":"166","author":"Chu X.M.","year":"2019","unstructured":"Chu X.M.; Wang C.; Wang W.L.; Liang L.L.; Liu W.; Gong K.K.; Sun K.L.; Triazole derivatives and their antiplasmodial and antimalarial activities. Eur J Med Chem 2019,166,206-223","journal-title":"Eur J Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejmech.2019.05.071","volume":"178","author":"Zhang J.","year":"2019","unstructured":"Zhang J.; Wang S.; Ba Y.; Xu Z.; Tetrazole hybrids with potential anticancer activity. Eur J Med Chem 2019,178,341-351","journal-title":"Eur J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"Gottesman M.M.","year":"2002","unstructured":"Gottesman M.M.; Mechanisms of cancer drug resistance. Annu Rev Med 2002,53,615-627","journal-title":"Annu Rev Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cclet.2016.07.024","volume":"28","author":"Jia X.D.","year":"2017","unstructured":"Jia X.D.; Wang S.; Wang M.H.; Liu M.L.; Xia G.M.; Liu X.J.; Chai Y.; He H.W.; Synthesis and in vitro antitumor activity of novel naphthyridinone derivatives. Chin Chem Lett 2017,28,235-239","journal-title":"Chin Chem Lett"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cclet.2016.07.032","volume":"28","author":"Xu Z.","year":"2017","unstructured":"Xu Z.; Zhang S.; Gao C.; Fan J.; Zhao F.; Lv Z.S.; Feng L.S.; Isatin hybrids and their anti-tuberculosis activity. Chin Chem Lett 2017,28,159-167","journal-title":"Chin Chem Lett"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/17460441.2017.1319357","volume":"12","author":"Musiol R.","year":"2017","unstructured":"Musiol R.; An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opin Drug Discov 2017,12(6),583-597","journal-title":"Expert Opin Drug Discov"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/jhet.3153","volume":"55","author":"Makhanya T.R.","year":"2018","unstructured":"Makhanya T.R.; Gengan R.M.; Pandian P.; Chuturgoon A.A.; Tiloke C.; Atar A.; Phosphotungstic acid catalyzed one pot synthesis of 4,8,8-trimethyl-5-phenyl-5,5a,8,9-tetrahydrobenzo[b] [1,8]naphthyridin-6(7H)-one derivatives and their biological evaluation against A549 lung cancer cells. J Heterocycl Chem 2018,55,1193-1204","journal-title":"J Heterocycl Chem"},{"key":"ref=13","first-page":"28","volume":"39","author":"Xie X.B.","year":"2018","unstructured":"Xie X.B.; Guo X.L.; Xu Y.; Xu Z.; Guan J.G.; Gao C.; Hybrids as antifungal, antitubercular and anticancer agents. World Notes on Antibiotics 2018,39,28-42","journal-title":"World Notes on Antibiotics"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ejmech.2016.08.039","volume":"124","author":"Shaveta","year":"2016","unstructured":"Shaveta ; Mishra S.; Singh P.; Hybrid molecules: The privileged scaffolds for various pharmaceuticals. Eur J Med Chem 2016,124,500-536","journal-title":"Eur J Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ar7000843","volume":"41","author":"Meunier B.","year":"2008","unstructured":"Meunier B.; Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008,41(1),69-77","journal-title":"Acc Chem Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1002\/jhet.3670","volume":"56","author":"Dan J.","year":"2019","unstructured":"Dan J.; Zhang G.F.; Moxifloxacin\/Gatifloxacin-1,2,3-triazole-isatin hybrids with hydrogen-bond donor and their in vitro anticancer activity. J Heterocycl Chem 2019,56,2691-2694","journal-title":"J Heterocycl Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ejmech.2018.11.032","volume":"162","author":"Xu Z.","year":"2019","unstructured":"Xu Z.; Zhao S.J.; Lv Z.S.; Gao F.; Wang Y.; Zhang F.; Bai L.; Deng J.L.; Fluoroquinolone-isatin hybrids and their biological activities. Eur J Med Chem 2019,162,396-406","journal-title":"Eur J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/jhet.3382","volume":"56","author":"Xu Z.","year":"2019","unstructured":"Xu Z.; Zhao S.J.; Deng J.L.; Wang Q.; Lv Z.S.; Ciprofloxacin-isatin hybrids and their antimycobacterial activities. J Heterocycl Chem 2019,56,319-324","journal-title":"J Heterocycl Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jhet.3386","volume":"56","author":"Xu Z.","year":"2019","unstructured":"Xu Z.; Zhao S.J.; Deng J.L.; Wang Q.; Lv Z.S.; Design, synthesis, and antimycobacterial activities of diethylene glycol tethered moxifloxacin-isatin hybrids. J Heterocycl Chem 2019,56,331-337","journal-title":"J Heterocycl Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ejmech.2017.06.051","volume":"138","author":"Zhang S.","year":"2017","unstructured":"Zhang S.; Xu Z.; Gao C.; Ren Q.C.; Chang L.; Lv Z.S.; Feng L.S.; Triazole derivatives and their anti-tubercular activity. Eur J Med Chem 2017,138,501-513","journal-title":"Eur J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ejmech.2019.02.055","volume":"168","author":"Zhang B.","year":"2019","unstructured":"Zhang B.; Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. Eur J Med Chem 2019,168,357-372","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103162","volume":"91,","author":"Gao F.","year":"2019","unstructured":"Gao F.; Ye L.; Kong F.; Huang G.; Xiao J.; Design, synthesis and antibacterial activity evaluation of moxifloxacin-amide-1,2,3-triazole-isatin hybrids. Bioorg Chem 2019,91,","journal-title":"Bioorg Chem"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T14:42:18Z","timestamp":1602081738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178750\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,7,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200128144825","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}